Terapias anti-TNF y neoplasias

Aggarwal, 1985, Characterization of receptors for human tumour necrosis factor and their regulation by gamma-interferon, Nature, 318, 665, 10.1038/318665a0 Okubo, 1990, Production of tumor necrosis factor-alpha by alveolar macrophages of lung cancer patients, Jpn J Cancer Res, 81, 403, 10.1111/j.1349-7006.1990.tb02582.x Ghezzi, 2005, Tumor necrosis factor as a pharmacological target, Mol Biotechnol, 31, 239, 10.1385/MB:31:3:239 Gelin, 1991, Role of endogenous tumor necrosis factor alpha and interleukin 1 for experimental tumor growth and the development of cancer cachexia, Cancer Res, 51, 415 Kiyama, 1994, The presence of tumor necrosis factor-alpha and its antibody in the sera of cachexic patients with gastrointestinal cancer, Surg Today, 24, 759, 10.1007/BF01636787 Williams, 2008, Antitumor necrosis factor-alpha therapy and potential cancer inhibition, Eur J Cancer Prev, 17, 169, 10.1097/CEJ.0b013e3282b6fcff Madhusudan, 2004, A phase II study of etanercept (Enbrel), a tumor necrosis factor alpha inhibitor in patients with metastatic breast cancer, Clin Cancer Res, 10, 6528, 10.1158/1078-0432.CCR-04-0730 Madhusudan, 2005, Study of etanercept, a tumor necrosis factor-alpha inhibitor, in recurrent ovarian cancer, J Clin Oncol, 23, 5950, 10.1200/JCO.2005.04.127 Brown, 2008, A clinical study assessing the tolerability and biological effects of infliximab, a TNF-alpha inhibitor, in patients with advanced cancer, Ann Oncol, 19, 1340, 10.1093/annonc/mdn054 Friedberg, 2008, Targeting the follicular lymphoma microenvironment through blockade of TNFalpha with etanercept, Leuk Lymphoma, 49, 902, 10.1080/10428190801950033 Jatoi, 2007, A placebo-controlled double blind trial of etanercept for the cancer anorexia/weight loss syndrome: results from N00C1 from the North Central Cancer Treatment Group, Cancer, 110, 1396, 10.1002/cncr.22944 Bongartz, 2006, Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials, JAMA, 295, 2275, 10.1001/jama.295.19.2275 Leombruno, 2008, The safety of anti-Tumor Necrosis Factor treatments in rheumatoid arthritis: meta and exposure adjusted pooled analyses of serious adverse events, Ann Rheum Dis Brown, 2002, Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration, Arthritis Rheum, 46, 3151, 10.1002/art.10679 Geborek, 2005, Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas, Ann Rheum Dis, 64, 699, 10.1136/ard.2004.030528 Askling, 2005, Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists, Ann Rheum Dis, 64, 1414, 10.1136/ard.2004.033241 Wolfe, 2004, Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients, Arthritis Rheum, 50, 1740, 10.1002/art.20311 Wolfe, 2007, The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation, Arthritis Rheum, 56, 1433, 10.1002/art.22579 Baecklund, 2006, Association of chronic inflammation, not its treatment, with increased lymphoma risk in rheumatoid arthritis, Arthritis Rheum, 54, 692, 10.1002/art.21675 Setoguchi, 2006, Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis, Arthritis Rheum, 54, 2757, 10.1002/art.22056 Abasolo, 2008, Is The Exposure To TNF Antagonists A Risk Factor For Cancer In Rheumatoid Arthritis? ACR/AHRP Anual Scientific Meeting, San Francisco, o Abasolo, 2008, Is The Incidence Risk Of Cancer Constant Through Time In Rheumatoid Arthritis Patients Exposed to Biologics? ACR/AHRP Anual Scientific Meeting, San Francisco, 1, o Carmona, 2007, All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists, Ann Rheum Dis, 66, 880, 10.1136/ard.2006.067660 Szekanecz, 2006, Malignancies and soluble tumor antigens in rheumatic diseases, Autoimmun Rev, 6, 42, 10.1016/j.autrev.2006.03.007 Abasolo, 2008, Cancer in rheumatoid arthritis: occurrence, mortality, and associated factors in a South European population, Semin Arthritis Rheum, 37, 388, 10.1016/j.semarthrit.2007.08.006 Askling, 2005, Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists, Ann Rheum Dis, 64, 1421, 10.1136/ard.2004.033993 Drini, 2008, Hepatosplenic T-cell lymphoma following infliximab therapy for Crohn's disease, Med J Aust, 189, 464, 10.5694/j.1326-5377.2008.tb02124.x Mackey, 2007, Hepatosplenic T cell lymphoma associated with infliximab use in young patients treated for inflammatory bowel disease, J Pediatr Gastroenterol Nutr, 44, 265, 10.1097/MPG.0b013e31802f6424 Zeidan, 2007, Hepatosplenic T-cell lymphoma in a patient with Crohn's disease who received infliximab therapy, Leuk Lymphoma, 48, 1410, 10.1080/10428190701345433 Nakashima, 2008, Diffuse large B-cell lymphoma in a patient with rheumatoid arthritis treated with infliximab and methotrexate, Clin Exp Dermatol, 33, 437, 10.1111/j.1365-2230.2007.02683.x Ziakas, 2003, Lymphoma development in a patient receiving anti-TNF therapy, Haematologica, 88 Smale, 2007, Monoclonal gammopathy of undetermined significance and anti-TNF-alpha treatment, Scand J Rheumatol, 36, 405, 10.1080/03009740701286904 Lees, 2008, Resolution of non-small-cell lung cancer after withdrawal of anti-TNF therapy, N Engl J Med, 359, 320, 10.1056/NEJMc0800250 Sheppard, 2007, Skin cancer in psoriatic arthritis treated with anti-TNF therapy, Rheumatology (Oxford), 46, 1622, 10.1093/rheumatology/kem214 Manfredsdottir, 2006, The effects of tobacco smoking and rheumatoid factor seropositivity on disease activity and joint damage in early rheumatoid arthritis, Rheumatology (Oxford), 45, 734, 10.1093/rheumatology/kei240 Aksu, 2007, Hodgkin's lymphoma following treatment with etanercept in ankylosing spondylitis, Rheumatol Int, 28, 185, 10.1007/s00296-007-0391-9 Askling, 2006, Risk for malignant lymphoma in ankylosing spondylitis: a nationwide Swedish case-control study, Ann Rheum Dis, 65, 1184, 10.1136/ard.2005.047514 Burstein, 2008, Colitis and cancer: a tale of inflammatory cells and their cytokines, J Clin Invest, 118, 464 Askling, 2005, Risk of haematopoietic cancer in patients with inflammatory bowel disease, Gut, 54, 617, 10.1136/gut.2004.051771 van Hogezand, 2002, Malignancies in inflammatory bowel disease: fact or fiction?, Scand J Gastroenterol Suppl, 48, 10.1080/003655202320621454 Bickston, 1999, The relationship between infliximab treatment and lymphoma in Crohn's disease, Gastroenterology, 117, 1433, 10.1016/S0016-5085(99)70294-5 Roddy, 2002, Non-Hodgkin's lymphoma in a patient with refractory dermatomyositis which had been treated with infliximab, Rheumatology (Oxford), 41, 1194, 10.1093/rheumatology/41.10.1194 Smedby, 2006, Autoimmune and chronic inflammatory disorders and risk of non-Hodgkin lymphoma by subtype, J Natl Cancer Inst, 98, 51, 10.1093/jnci/djj004 Knight, 2002, Cancer incidence in a population-based cohort of patients with Wegener's granulomatosis, Int J Cancer, 100, 82, 10.1002/ijc.10444 Stone, 2006, Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial, Arthritis Rheum, 54, 1608, 10.1002/art.21869 Sociedad Española de Reumatología. Guía de Práctica Clínica para el Manejo de la Artritis reumatoide. 2007 [cited; Available from: http://www.ser.es/practicaClinica/GUIPCAR_2007/Seguridad/Menu6_Seguridad_Anti-TNFs_VI2.php Furst, 2007, Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007, Ann Rheum Dis, 66, iii2, 10.1136/ard.2007.081430 Dixon WG, Watson KD, Lunt M, BSRBR Control Centre Consortium. Hyrich KL, Symmons DPM, et al. The Influence of Anti-TNF Therapy upon Cancer Incidence in Patients with Rheumatoid Arthritis (RA) who have had Prior Malignancy: Results from the BSRBR. ACR/AHRP Anual Scientific Meeting; 2008 October 24–28; San Francisco 2008; p. O–1264.